Antimicrobial resistance represents one of the most urgent global health challenges. Xenova Biosciences is focused on developing targeted, biology-driven therapies that selectively eliminate pathogenic bacteria while preserving the normal microbiome.

Our lead programme addresses carbapenem-resistant E. coli and Klebsiella pneumoniae infections in patients with limited or no effective treatment options.

Our approach:

• Precision bacteriophage therapeutics

• Strictly lytic, genomically characterised phages

• Scalable, GMP-aligned manufacturing

• Regulatory-focused development strategy